来源丨新华社 编辑丨曾静娇 SFC 报道没有对这些英国官员的身份作具体说明。报道称，预计未来几天，美军重型轰炸机将抵达 位于查戈斯群岛主岛迪戈加西亚岛以及位于英国格洛斯特郡费尔福德的英军基地。据报道，这 些轰炸机将从上述基地出发，攻击伊朗的地下导弹设施。 英国媒体此前报道，英国曾以国际法为由，拒绝美国使用查戈斯群岛上的军事基地打击伊朗。 斯塔默1日晚发表声明称， 已同意美国使用该军事基地用于"特定且有限"的防御目的。 据新华社援引英国《卫报》4日报道称， 英国官员表示英国"并未排除未来参与打击伊朗弹道 导弹发射装置的可能性"。 ...

据新华社报道，美国和以色列对伊朗发动的军事打击4日进入第五天。伊朗方面表示，原定于4 日晚开始举行的已故最高领袖哈梅内伊告别仪式被推迟，伊朗已确定最高领袖的几位候选人。 以方称，以军对多处目标进行打击，任何成为伊朗最高领袖、对抗以色列和美国的人都将成 为"清除目标"。美国防长赫格塞思称，美以要在一周内"完全控制"伊朗领空。 ——伊朗 据伊朗媒体报道，原定于4日晚开始举行的已故最高领袖哈梅内伊告别仪式被推迟，原因是"预 计前来吊唁的民众数量空前庞大"。 伊朗法尔斯通讯社援引知情人士消息报道说， 伊朗最高领袖选举可能推迟到下周。 已采取最 高级别安全措施，确保专家会议顺利选举最高领袖。选举可能在哈梅内伊葬礼后以在场方式举 行。 伊朗媒体报道说， 伊朗已确定最高领袖的几位候选人 ，即将从中选出最高领袖。报道援引伊 朗专家会议成员艾哈迈德·哈塔米的话说，伊朗将"第一时间"选出最高领袖。哈塔米未透露更 多细节。 伊朗伊斯兰革命卫队海军副司令穆罕默德·阿克巴尔扎德表示， 霍尔木兹海峡已完全处于伊朗 海军的控制之下，十多艘油轮在该海峡被炮弹击中。 伊朗军方发布公告说，过去24小时，共计击落35架美以无人机。另据伊朗媒体报道 ...

Your favorite crypto project? ...

Where Is Sports Betting Legal? A Guide To All 50 States https://t.co/7LY1MRlOJk (Illustration: Getty Images) https://t.co/5KDeuSvDaF ...

Pulmonx (NasdaqGS:LUNG) Q4 2025 Earnings call March 04, 2026 04:30 PM ET Speaker2Thank you for standing by. Welcome to the Pulmonx fourth quarter 2025 earnings conference call. At this time, all participants are in listen only mode. After the speaker's presentation, we'll open up for questions. To ask a question during the session, you will need to press star 11 on your telephone. You'll hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be ...

Financial Data and Key Metrics Changes - Revenue for Q4 2026 was $109 million, up 3% sequentially and 7% year-over-year, marking a strong finish to the fiscal year [4][18] - Non-GAAP gross margin remained at a record high of 33%, flat sequentially and up 3 percentage points year-over-year [18] - Non-GAAP adjusted EBITDA loss was $18 million, an improvement from a loss of $19 million in the prior quarter [20] - Full fiscal year 2026 revenue was $411 million, with non-GAAP gross margin at 32% [23] Business Line Data and Key Metrics Changes - Network charging systems accounted for $58 million, or 53% of Q4 revenue, up 2% sequentially and 10% year-over-year [18] - Subscription revenue reached $42 million, representing 39% of total revenue, up 1% sequentially and 11% year-over-year [18] - Hardware gross margin remained flat sequentially, while subscription margin reached a new GAAP record of 64% [19] Market Data and Key Metrics Changes - North America contributed 77% of revenue, while Europe accounted for 23%, with Europe achieving its highest share of revenue since going public [19] - The company managed approximately 385,000 ports globally, including over 41,000 DC fast chargers [16] Company Strategy and Development Direction - The company is focused on operational excellence and innovation, supported by partnerships and leadership additions [4][12] - A new mobile app update is expected to enhance user experience and drive increased utilization [11] - The company is leveraging AI to improve operational efficiency and product innovation [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trend, expecting acceleration as new products ramp up [5] - The EV market fundamentals remain strong, with sustained global EV adoption and high satisfaction among EV owners [8] - The company anticipates a typical seasonal decline in Q1 revenue, guiding for $90 million to $100 million [23] Other Important Information - The company has introduced new key performance indicators to align strategy with market performance [14] - Cash utilization from operations was minimal, with a significant reduction in cash usage from normal operations over the past year [22] Q&A Session Summary Question: Update on eVTOL opportunity - The company has not focused much on eVTOLs but is investing in understanding charging requirements for autonomous vehicles [26][27] Question: Opportunities for cost reduction and price increases - The company has not pushed price increases and expects gross margin improvement through new hardware platforms [28][29] Question: Reconciliation of user growth and revenue guidance - Revenue guidance reflects typical seasonality and a prudent approach to the current macro environment [35][36] Question: Update on NEVI and domestic content requirements - Obligated funds are not expected to be affected by rule changes around domestic content [38][39] Question: Pathway to positive EBITDA - The company expects gradual improvement in growth, gross margins, and OpEx control to reach positive EBITDA [66][67]

Core Viewpoint - Itafos Inc. will release its financial results for Q4 2025 and the full year 2025 on March 18, 2026, with a recorded webcast available on March 23, 2026, to discuss these results and provide business updates [1]. Company Overview - Itafos is a phosphate and specialty fertilizer company with operations across three continents, headquartered in Houston, Texas, and trading on the TSX Venture Exchange under the ticker "IFOS" and on the OTCQX under "ITFS" [2]. Production Capacity - The company has several production facilities: - Conda, Idaho, US: - Approximately 550,000 tons per year of MAP, MAP+, SPA, merchant grade phosphoric acid, and APP - Approximately 27,000 tons per year of hydrofluorosilicic acid [7] - Arraias, Tocantins, Brazil: - Proposed production targets include approximately 275,000 tons per year of single superphosphate, PAPR, and DAPR - Additional targets of approximately 170,000 tons per year of SSP, 60,000 tons per year of PAPR, and 45,000 tons per year of DAPR - Approximately 40,000 tons per year of excess sulfuric acid [7] - Farim, Guinea-Bissau: A high-grade phosphate mine project [7] - Santana, Pará, Brazil: A vertically integrated high-grade phosphate mine and fertilizer plant project [7]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $8.4 million, down from $10.8 million in Q4 2024, primarily due to a decline in license revenue, partially offset by an increase in milestone revenue [22] - For the full year 2025, revenue was $18.7 million compared to $26.4 million in 2024, attributed to declines in both license and milestone revenue [25][26] - The net loss for Q4 2025 was $14.2 million or $0.11 per share, compared to a net loss of $13.1 million or $0.12 per share in the prior year [25] - The full year net loss was $64.8 million or $0.57 per share, compared to a net loss of $62 million or $0.61 per share in 2024 [27] Business Line Data and Key Metrics Changes - The company had 107 active partners and 407 active programs by year-end 2025, reflecting growth in both partnerships and program activity [4][6] - There were 84 program additions in 2025, significantly higher than previous years, with a net increase of 44 programs during the year [9] - Over 98% of active programs have contracted future economics to the company, with over $3 billion in total contracted milestone payments [10] Market Data and Key Metrics Changes - The majority of partners are based in the U.S., with others primarily in Europe and Asia, indicating a diversified partner base [7] - Eight of the ten largest pharmaceutical companies are active partners, showcasing the strength of the company's technology [8] Company Strategy and Development Direction - The company introduced OmniUltra, a transgenic chicken platform, which is expected to drive growth and attract new partners [5][19] - The xPloration platform is positioned for significant growth, with an expanding pipeline and increasing partner engagement [5][20] - The company aims to transition from milestone-driven revenue to more royalty-driven revenue, with an average royalty rate of 3.4% across its portfolio [31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory towards positive cash flow, supported by a scalable business model and controlled operating costs [6][31] - The company anticipates a strong year in 2026 with potential value-creating events and expects revenue to be in the range of $25 million to $30 million [29][30] Other Important Information - The company ended 2025 with $54 million in cash equivalents and short-term investments [28] - Operating expenses decreased to $87.6 million in 2025 from $100.9 million in 2024, reflecting cost control measures [26] Q&A Session Summary Question: Impact of market conditions on new program growth - Management noted strong momentum in program additions in 2025 and expressed optimism for continued growth in 2026, driven by new technologies [34][36] Question: Growth expectations for xPloration - Management indicated strong demand for xPloration, with expectations for significant revenue growth from instrument sales and consumables [37][39] Question: Cash flow neutrality and investment strategy - Management emphasized the importance of maintaining cash flow neutrality while also investing in technologies that meet industry needs [42][45] Question: Timeline for achieving cash flow break-even - While no precise date was provided, management expressed confidence in reaching break-even due to the growing portfolio of partner programs [53][54] Question: Interest in xPloration from new partners - Management confirmed that xPloration is attracting both existing and new partners, enhancing relationships and creating new opportunities [71][73] Question: Milestones expected from OmniUltra - The initial focus for OmniUltra will be on adding partners and programs, with expectations for continued engagement and development [74]

Core Viewpoint - Pangaea Logistics Solutions will release its fourth quarter 2025 financial results on March 10, 2026, after market close [1] Company Summary - Pangaea Logistics Solutions is identified as a global provider of comprehensive maritime logistics solutions [1]

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [5][21] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million compared to $8.6 million in 2024 [5][23] - The company ended the year with $64.8 million in cash and no debt, reinforcing financial stability [5][26] Business Line Data and Key Metrics Changes - Revenue from Tru Niagen grew by 21% to $27.5 million, primarily driven by e-commerce sales of $20.2 million, up 17% [23][24] - Niagen ingredient revenue was $5.6 million, a 5% increase year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [24] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [24] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home injection kits through a telehealth platform in 2026 [8] - The company anticipates continued growth in Asia-Pacific markets and selective retail channels [47] Company Strategy and Development Direction - The company aims to focus on NAD science and has divested non-core activities, such as the sale of the ChromaDex Reference Standards business [11][29] - Plans include launching Niagen Plus branded at-home injection kits and expanding into the beauty cosmetics market [8][9] - The company is pursuing litigation against the FDA regarding NMN products, believing it has a strong case [9][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong performance in 2026 despite increased competition in the NAD space [6][31] - The company expects 10%-15% growth in net sales for 2026, with a slight improvement in gross margin due to supply chain efficiencies [29][30] - Management emphasized the importance of scientific integrity and continued investment in R&D to support innovation [25][30] Other Important Information - The company secured a patent for intravenous and injectable formulations of NR, indicating potential for new product offerings [8] - Management highlighted the therapeutic potential of NR supplementation based on recent studies, including benefits for long COVID and cognitive health [14][16] Q&A Session Summary Question: Discussion on injections and SKUs - The company plans to start with one SKU for injections, targeting the biohacker community and those interested in longevity interventions [35][36] Question: Guidance for the year - Management indicated that guidance is conservative, reflecting a cautious approach to revenue projections [40] Question: Growth drivers for the year - Growth is expected from existing products, new IV and beauty products, and expanded distribution channels [46][47] Question: Lawsuit against the FDA - Management believes the lawsuit will not significantly impact costs and anticipates a summary judgment [56][57] Question: Share repurchase strategy - The company plans to utilize its $10 million buyback program more actively in the future [60]